Agomab Therapeutics (AGMB) Registration Filing summary

Company overview and business model

• Clinical-stage biopharmaceutical company developing disease-modifying therapies for immunology and inflammatory diseases, focusing initially on chronic fibrotic indications with high unmet medical need.

• Lead product candidates: ontunisertib (oral, GI-restricted ALK5 inhibitor for fibrostenosing Crohn's disease) and AGMB-447 (inhaled ALK5 inhibitor for idiopathic pulmonary fibrosis).

• Pipeline includes preclinical programs, notably AGMB-101, an HGF-mimetic monoclonal antibody for liver cirrhosis.

• Retains exclusive, worldwide development and commercialization rights to all product candidates.

• Strategy leverages established biological pathways and validated modalities to increase efficacy and minimize systemic toxicity.

Financial performance and metrics

• No product revenue to date; operations funded by €299.7 million in equity from strategic and institutional investors.

• Net losses: €46.3 million (2024), €11.4 million (2023); accumulated loss of €164.3 million as of September 30, 2025.

• R&D expenses: €39.3 million (2024), €26.3 million (2023); G&A expenses: €10.1 million (2024), €6.1 million (2023).

• Cash and cash equivalents: €129.6 million as of September 30, 2025.

• Operating cash outflows: €38.6 million for the nine months ended September 30, 2025.

Use of proceeds and capital allocation

• Net proceeds from the IPO, together with existing cash, will fund clinical development of ontunisertib (Phase 2b in FSCD) and AGMB-447 (Phase 2 in IPF), advancement of preclinical candidates, milestone payment for Origo Biopharma acquisition, G&A expenses, and working capital.

• Management retains broad discretion over allocation of net proceeds.